A 39-year-old unvaccinated Franklin County woman has died after a recent measles diagnosis. Nationally, numbers continue to increase and the US has passed 4,000 cases.
|Articles|September 24, 2020
FDA Authorizes Point-of-Care SARS-CoV-2 Antibody Test
Author(s)Kevin Kunzmann
The EUA grants clinicians and caregivers capability to provide serologic assay results in person to potentially infected patients.
Advertisement
The US Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the first point-of-care serologic antibody test in potential patients with
The EUA is actually a reissue, to the Assure COVID-19 IgG/IgM Rapid Test Device, which was first authorized for emergency use in indicated labs for identifying SARS-CoV-2 antibodies in individuals this July. The newest EUA now authorizes the device to be used for testing fingerstick blood samples in point-of-care settings including physician’s offices, hospitals, urgent care facilities, and the emergency room for in-person results.
Approximately 50 serologic tests have been granted an EUA by the FDA since the beginning of the COVID-19 pandemic. This lateral flow assay is authorized for use with venous whole blood, serum, plasma, and fingerstick whole blood.
The matters of SARS-CoV-2 antibody development, immunity, and persistence are not wholly understood in the ongoing research of immune response to the virus. As such, the FDA stressed with this newest available antibody test that patients should not use antibody test results as any indication to lessen their preventive measures against COVID-19 infection to themselves or those around them.
Social distancing, mask wearing, or returning to work should not be determined by antibody test results.
That said, FDA Commissioner Stephen M. Hahn, MD emphasized in a
“Until today, serology test samples were generally only able to be evaluated in a central lab, which can be time consuming and use additional resources to transport samples and run the test,” he said. “As more and more point-of-care serology tests are authorized, they will help conserve those resources and may help reduce processing time for other types of COVID-19 tests, as less time is spent on serology tests."
Advertisement
Related to this article
The National Foundation for Infectious Diseases (NFID) recently held its respiratory season kick-off, which included the release of its annual respiratory disease survey. This year, the survey revealed the gap between vaccine support and uptake. Robert Hopkins Jr, MD, medical director of NFID delves deeper into the findings of the survey and the vaccine uptake challenges associated with certain immunizations.
The latest CDC numbers show a 5.0% increase of measles cases from week-to-week. The US total reached 4080 confirmed cases, 78% above all of 2025.
With US measles cases nearing 3,900 this year and Pennsylvania reporting its fifth measles-related death, here is a review of how the virus spreads, how it is prevented and managed, and what severe disease looks like.
Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate met every prespecified primary immunogenicity and safety endpoint against PCV20 and PCV21 in the OPUS-1 trial of 4,047 US adults.
Irkutsk anti-plague institute death prompts quarantines and conflicting official accounts.
A laboratory technician at a Siberian anti-plague institute has died of pneumonia of unknown cause, prompting quarantines and contact monitoring while Russian officials stop short of confirming plague.
A study finding clesrovimab comparable to palivizumab in protecting at-risk infants in their first RSV season was extended to demonstrate clesrovimab effective and well-tolerated when administered in their second season.
Advertisement
Advertisement